In our experience, from a series of 80 patients (median age: 69, range: 65–84) treated with various approaches, the median survival from relapse was six months (Figure 1), with a small survival advantage for patients with core binding factor (CBF) AML, (i.e., AML with t[8;21] or inv[16]/t[16;16]) accounting for 8% of cases and AML relapsing with low marrow blast cell count, resembling myelodysplastic syndrome, as shown in Figure 2. Here, CEBPZ is linked to acute myeloid leukemia.